AstraZeneca PLC (AZN)
| Market Cap | 285.54B +37.3% |
| Revenue (ttm) | 60.44B +9.9% |
| Net Income | 10.39B +33.7% |
| EPS | 6.64 +33.6% |
| Shares Out | 1.55B |
| PE Ratio | 27.48 |
| Forward PE | 17.32 |
| Dividend | $3.20 (1.73%) |
| Ex-Dividend Date | Feb 20, 2026 |
| Volume | 1,793,655 |
| Open | 185.45 |
| Previous Close | 187.37 |
| Day's Range | 184.01 - 187.18 |
| 52-Week Range | 131.03 - 212.71 |
| Beta | 0.28 |
| Analysts | Strong Buy |
| Price Target | n/a |
| Earnings Date | Apr 29, 2026 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial StatementsNews
AstraZeneca Prostate Drug Wins FDA Panel Backing As Breast Cancer Candidate Falters
The U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) delivered mixed recommendations for AstraZeneca Plc (NASDAQ:AZN), endorsing its prostate cancer regimen while declinin...
AstraZeneca stock falls after FDA panel votes against new cancer drug
An advisory panel for the U.S. Food and Drug Administration voted 6-3 against AstraZeneca's oral drug camizestrant intended for a type of breast cancer tumor, citing concerns around trial design. Astr...
AstraZeneca: FDA Panel Recommends Truqap Combination For PTEN-Deficient Prostate Cancer
(RTTNews) - AstraZeneca (AZN) announced that the U.S. FDA's Oncologic Drugs Advisory Committee (ODAC) has recommended approval of Truqap in combination with abiraterone and androgen deprivation therap...
AstraZeneca's Breast-Cancer Candidate Drug Loses FDA Panel Vote
The British pharmaceutical group said it would continue to work with U.S. regulators on a review of its breast-cancer candidate after the drug failed to get backing at a key advisory committee vote.
AstraZeneca shares drop after US regulatory panel votes against breast cancer drug
Shares of AstraZeneca fell 1.7% on Friday after an advisory panel for the U.S. Food and Drug Administration overnight voted against recommending the British drugmaker's experimental breas...
AstraZeneca (AZN) Receives Positive FDA Advisory for Truqap in Prostate Cancer Treatment
AstraZeneca (AZN) Receives Positive FDA Advisory for Truqap in Prostate Cancer Treatment
AstraZeneca (AZN) Faces FDA Advisory Committee Vote on Camizestrant
AstraZeneca (AZN) Faces FDA Advisory Committee Vote on Camizestrant
AstraZeneca (AZN) Faces Setback, But Analyst Stays Bullish
AstraZeneca (AZN) Faces Setback, But Analyst Stays Bullish
AstraZeneca (AZN) Faces Setback as FDA Panel Rejects Breast Cancer Drug
AstraZeneca (AZN) Faces Setback as FDA Panel Rejects Breast Cancer Drug
AstraZeneca (AZN) Faces Setback as FDA Advisory Panel Questions Drug's Benefit
AstraZeneca (AZN) Faces Setback as FDA Advisory Panel Questions Drug's Benefit
FDA panel votes against backing AstraZeneca's breast cancer drug
A panel of outside experts to the U.S. Food and Drug Administration voted against backing the risk-benefit profile of AstraZeneca's breast cancer drug, the company said on Thursday.
How AstraZeneca’s 17,000 AI-certified employees are helping it reach a ‘stretch goal’ of $80 billion in revenue
CFO Aradhana Sarin breaks down the building blocks behind the revenue target and reflects on a strong Q1.
AstraZeneca PLC (AZN) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
AstraZeneca PLC (AZN) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements
Q1 2026 AstraZeneca PLC Earnings Call Transcript
Q1 2026 AstraZeneca PLC Earnings Call Transcript
Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca
Option exercise triggers $25M payment to Pinetree. CAMBRIDGE, Mass.
Big pharma can boost Britain: Labour must not let our flagship firms drift away, says RUTH SUNDERLAND
One area where the UK still performs well on an international stage is pharmaceuticals, led by AstraZeneca and GSK.
AstraZeneca (AZN) Announces £300 Million Investment in UK Following Strong Q1 Performance
AstraZeneca (AZN) Announces £300 Million Investment in UK Following Strong Q1 Performance
AstraZeneca (AZN) and GSK Report Strong Q1 Earnings Amid Pricing Policy Concerns
AstraZeneca (AZN) and GSK Report Strong Q1 Earnings Amid Pricing Policy Concerns
AstraZeneca Flexes Cancer Drugs Performance, Pipeline Strength
AstraZeneca Plc (NASDAQ: AZN) on Wednesday reported first-quarter 2026 results that topped Wall Street estimates, driven by strong oncology and rare disease performance. The company posted revenue of...
AstraZeneca Earnings Call Transcript: Q1 2026
Q1 2026 saw 8% revenue growth and 12% operating profit growth, led by strong oncology and rare disease performance, while BioPharmaceuticals faced headwinds from loss of exclusivity. Four positive phase III readouts and 14 new approvals support a robust outlook through 2030.
AstraZeneca makes surprise U-turn with £300m pharma investment
Drugmaker had stalled large-scale UK projects but has now pledged investment at two sites, announced by Keir Starmer Britain’s biggest drugmaker AstraZeneca has said it will invest £300m in the UK in ...
Astrazeneca tops expectations in the first quarter on strong cancer drug sales
Astrazeneca is reporting first-quarter profit of $3.08 billion. The Cambridge, Britain-based company reported net income of 99 cents per share on Wednesday.
AstraZeneca (AZN) and GlaxoSmithKline (GSK) Exceed Q1 Earnings Expectations
AstraZeneca (AZN) and GlaxoSmithKline (GSK) Exceed Q1 Earnings Expectations
AstraZeneca (AZN) Forecasts Moderate Revenue Growth Through FY26
AstraZeneca (AZN) Forecasts Moderate Revenue Growth Through FY26